Dapirolizumab Pegol for Lupus
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial aims to evaluate the safety and tolerability of dapirolizumab pegol, a medication that helps manage health conditions by calming overactive immune responses in patients needing ongoing treatment.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
Is Dapirolizumab Pegol safe for humans?
What makes the drug Dapirolizumab Pegol unique for treating lupus?
Dapirolizumab Pegol is unique because it blocks the CD40 ligand, which is involved in activating immune cells, potentially reducing inflammation in lupus without the increased risk of blood clots seen with similar treatments. It is a PEGylated (attached to polyethylene glycol) antibody fragment, which may improve its stability and reduce side effects.12345
What data supports the effectiveness of the drug Dapirolizumab Pegol for treating lupus?
Research shows that Dapirolizumab Pegol, which blocks a protein called CD40L involved in immune responses, has been well tolerated and led to improvements in lupus disease activity in clinical trials. It increased the likelihood of patients responding positively to treatment, suggesting it could be an effective option for managing lupus.12345
Who Is on the Research Team?
UCB Cares
Principal Investigator
001 844 599 2273 (UCB)
Are You a Good Fit for This Trial?
This trial is for individuals who have completed a previous study on systemic lupus erythematosus within the last 4 weeks and could benefit from further treatment. Those with life-threatening conditions, ongoing cancer, or medical/psychiatric issues that may compromise their participation are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive dapirolizumab pegol treatment to evaluate long-term safety and tolerability
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension
Participants may continue to receive dapirolizumab pegol treatment long-term
What Are the Treatments Tested in This Trial?
Interventions
- Dapirolizumab Pegol
Find a Clinic Near You
Who Is Running the Clinical Trial?
UCB Biopharma SRL
Lead Sponsor
Jean-Christophe Tellier
UCB Biopharma SRL
Chief Executive Officer since 2015
MD from University of Reims Champagne-Ardenne, Rheumatology specialization from University of Paris V, Executive business programs at Harvard and INSEAD
Dr. Iris Loew-Friedrich
UCB Biopharma SRL
Chief Medical Officer since 2014
MD from University of Leuven, PhD in Medical Sciences from University of Leuven